Sagespring Wealth Partners LLC Invests $71,000 in Accolade, Inc. (NASDAQ:ACCD)

Sagespring Wealth Partners LLC purchased a new stake in Accolade, Inc. (NASDAQ:ACCD) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 20,854 shares of the company’s stock, valued at approximately $71,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Stifel Financial Corp boosted its position in shares of Accolade by 20.8% during the third quarter. Stifel Financial Corp now owns 332,126 shares of the company’s stock valued at $1,279,000 after buying an additional 57,239 shares during the last quarter. Barclays PLC grew its stake in shares of Accolade by 164.4% in the 3rd quarter. Barclays PLC now owns 139,901 shares of the company’s stock worth $539,000 after acquiring an additional 86,981 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Accolade by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,782,038 shares of the company’s stock valued at $6,862,000 after purchasing an additional 83,556 shares during the last quarter. Pallas Capital Advisors LLC bought a new position in shares of Accolade during the fourth quarter valued at about $38,000. Finally, Nisa Investment Advisors LLC boosted its holdings in Accolade by 15,113.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 55,680 shares of the company’s stock worth $190,000 after purchasing an additional 55,314 shares during the last quarter. Institutional investors and hedge funds own 84.99% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ACCD. William Blair cut shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Leerink Partnrs cut Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Stifel Nicolaus reaffirmed a “hold” rating and set a $7.03 target price (down from $8.00) on shares of Accolade in a research report on Thursday, January 9th. Leerink Partners reissued a “market perform” rating on shares of Accolade in a report on Wednesday, January 8th. Finally, Raymond James restated a “market perform” rating on shares of Accolade in a report on Thursday, January 9th. Thirteen research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $6.51.

Accolade Price Performance

ACCD opened at $7.02 on Friday. Accolade, Inc. has a 12 month low of $3.08 and a 12 month high of $9.67. The company has a market cap of $575.59 million, a PE ratio of -3.12 and a beta of 2.10. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67. The company has a 50 day moving average of $6.97 and a 200 day moving average of $5.28.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.